Impilo has undertaken to subscribe for shares in a directed share issue carried out by Stille AB (publ). Impilo’s subscription undertaking, which corresponds to an investment amount of approximately SEK 220 million, is conditional upon e.g. an extraordinary general meeting of Stille approving the directed share issue, and Impilo’s investment being approved by the Inspectorate of Strategic Products (Sw. Inspektionen för strategiska produkter) in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar).
Stille AB develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s share is listed on Nasdaq First North Growth Market.
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in medical technology, pharmaceuticals, healthcare services, and other health-related areas.
Impilo is advised by Mannheimer Swartling in connection with the investment in Stille.